Company: NIVFW
Filing Date: 2025-06-03
Form Type: 424B3
Source: 0001213900-25-050825
Chunk: 157

Company: NewGenIvf Group Ltd
Filing Date: 2025-06-03
Form: 424B3
Chunk 157
---
 York, NY 10119. |

| (4) | The business address of White Lion is 17631 Ventura Blvd, Suite 1008, Encino, CA 91316               |
| (5) | The business address of Genetics & IVF Institute, Inc. is 3015 Williams Drive, Fairfax VA 22031, USA |
| (6) | The business address of A SPAC (Holdings) Limited is Ritter House, Wickhams Cay, II, PO Box 3170,    
 Road Town, Tortola VG1110, British Virgin Islands.                                                   |

| (7) | This column lists the number of our ordinary shares beneficially owned by this                                                                
 Selling Securityholder as of June 2, 2025 after giving effect to the Maximum Percentage (as defined in the paragraph above). Without regard   
 to the Maximum Percentage, as of June 2, 2025, this Selling Shareholder would beneficially own an aggregate of 14,687,027 of our Ordinary     
 Shares (of which 12,000,000 shares are being registered for resale under this prospectus), consisting of (i) 2,682,344 shares underlying      
 the Fourth Tranche Note held by this Selling Securityholder, convertible at an alternate conversion price of $0.2388, (ii) 10,537,780         
 shares underlying the Additional Remaining Notes to be acquired by this Selling Securityholder, convertible at an alternate conversion        
 price of $0.2388, (iii) 1,132,869 shares underlying the Series A Warrants held by this Selling Securityholder, currently exercisable at       
 an exercise price of $0.9203, (iv) 7,425 shares underlying the Series B Warrants held by this Selling Securityholder, the exercise price      
 of the Series B Warrants was prepaid, except for a nominal exercise price of $0.001 per share, and (v) 326,609 shares underlying the Exchange 
 Warrants held by this Selling Shareholder.                                                                                                    |

| (8) | In accordance with the terms of the Registration                                                                                   
 Rights Agreement (as defined below) with this Selling Securityholder, for purposes of the calculations of ordinary shares to       
 be sold by this Selling Securityholder pursuant to the prospectus we are assuming (i) an event of default under the Fourth Tranche 
 Note and the Additional Remaining Notes has not occurred and the issuance of 250% of the ordinary shares underlying the Fourth     
 Tranche